Physician profile
Marium Khan
NPI 1922539493
$3,702.82
in general payments reported to CMS, 2019-2025
15 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $626 · 2023: $1,658 · 2024: $993 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,799.37 |
| Education | $151.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,103.71 | 2021-2025 | Tagrisso, Breztri, Fasenra |
| Pulmonx Corporation | $550.24 | 2022-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Genzyme Corporation | $272.07 | 2023-2024 | |
| Ethicon INC. | $251.20 | 2024 | Monarch Platform |
| Alexion Pharmaceuticals, INC. | $221.93 | 2022-2023 | Soliris |
| Glaxosmithkline, LLC. | $217.85 | 2022-2023 | Nucala |
| United Therapeutics Corporation | $208.71 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $188.61 | 2023 | Opsumit, Uptravi |
| Exelixis INC. | $162.17 | 2023 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $124.96 | 2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.97 | 2022 | |
| Verona Pharma, INC. | $120.90 | 2025 | Ohtuvayre |
| Insmed, INC. | $109.87 | 2023 | Arikayce |
| Cook Medical LLC | $32.21 | 2023-2024 | Blue Rhino, Melker |
| Neurelis, INC. | $16.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marium Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.